Cedar believes we are in a renaissance period for healthcare. Greater scientific understanding, technological advances, regulatory progressiveness, harmonization in global clinical trial standards, a burgeoning life sciences ecosystem, and increasing availability of capital have created an unprecedented environment for biotechnology, pharmaceutical, medical device, and diagnostic companies.
Separately, the alarming growth rate of healthcare expenditures has exposed systemic inefficiencies which have created opportunities for insurance, healthcare services, and digital health firms. Significant legislative and regulatory overhauls have empowered these companies to counter the current cost trend and drive value across the supply chain.
Empowered by a focused yet flexible investment mandate, Cedar looks to capitalize on the opportunities and players that are best positioned to benefit from an evolving healthcare landscape.